Robotic surgery player Medrobotics raises $25M; Neuravi begins enrollment in FDA trial of its stroke-fighting device;

@FierceMedDev: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. Article | Follow @VarunSaxena2

@EmilyWFierce: Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. FiercePharma article | Follow @EmilyWFierce

> Stent thrombectomy player Neuravi announced that the first patient has enrolled in the international pivotal trial of its CE-marked EmboTrap device to treat stroke. The study data will form a key plank of the company's submission for FDA approval. More

> Medrobotics announced a $25 million preferred stock financing to support commercialization of the Flex Robotic System for minimally invasive surgery. More

Biotech News

@FierceBiotech: Gilead wins FDA approval for a new HIV combo pill with rivals at its heels. Report | Follow @FierceBiotech

@JohnCFierce: Andy Futreal at MD Anderson is joining my Big Data:2025 panel at . | Follow @JohnCFierce

> AstraZeneca poaches ZS Pharma for $2.7B, beating Actelion to the punch. Report

> Sanofi bets another $1.7B on diabetes to pad its lagging pipeline. Story

> Under Pfizer's gaze, Allergan's Saunders softens his tone on early-stage R&D. Article

Pharma News

@FiercePharma: Australia looks to save cash by cutting scripts for common drugs. FiercePharmaAsia report | Follow @FiercePharma

@EricPFierce: makes sure Denmark gets some of the action as it starts massive build up. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. FiercePharmaMarketing story | Follow @CarlyHFierce

> Medicaid calls on Gilead, AbbVie to answer hep C drug pricing questions. Report

> Dr. Reddy's feels FDA heat, gets warning letter for three plants. Story

> Sanofi puts 2 units on the block, commits to $1.6B in cuts to turn business around. Article